var data={"title":"Fluocinonide: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Fluocinonide: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6211?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=fluocinonide-drug-information\" class=\"drug drug_general\">see &quot;Fluocinonide: Drug information&quot;</a> and <a href=\"topic.htm?path=fluocinonide-patient-drug-information\" class=\"drug drug_patient\">see &quot;Fluocinonide: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172332\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Vanos</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172333\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Lidemol;</li>\n      <li>Lidex;</li>\n      <li>Lyderm;</li>\n      <li>Tiamol;</li>\n      <li>Topactin;</li>\n      <li>Topsyn</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052884\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Adrenal Corticosteroid</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anti-inflammatory Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Corticosteroid, Topical</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Glucocorticoid</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052879\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=fluocinonide-drug-information\" class=\"drug drug_general\">see &quot;Fluocinonide: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Atopic dermatitis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream, gel, ointment, topical solution (0.05%): Children and Adolescents: Topical: Apply thin layer to affected area 2 to 4 times daily depending on the severity of the condition. <b>Note:</b> In children &lt;12 years, NICE guidelines recommend applying only once or twice daily (NICE 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream (0.1%): Children &ge;12 years and Adolescents: Topical: Apply a thin layer once daily to affected areas. Not recommended for use &gt;2 consecutive weeks or &gt;60 g/week total exposure. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Corticosteroid-responsive dermatoses (including psoriasis): </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream, gel, ointment, topical solution (0.05%): Children and Adolescents: Topical: Apply thin layer to affected area 2 to 4 times daily depending on the severity of the condition; may use occlusive dressings to manage psoriasis or recalcitrant conditions</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream (0.1%): Children &ge;12 years and Adolescents: Topical: Apply a thin layer once or twice daily to affected areas. Not recommended for use &gt;2 consecutive weeks or &gt;60 g/week total exposure. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassess diagnosis. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Atopic dermatitis:</b> Cream (0.1%): Topical: Apply thin layer to affected areas once daily. Not recommended for use &gt;2 consecutive weeks or &gt;60 g/week total exposure. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Psoriasis:</b> Cream (0.1%): Topical: Apply a thin layer once or twice daily to affected areas. Not recommended for use &gt;2 consecutive weeks or &gt;60 g/week total exposure. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassess diagnosis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Other inflammatory and pruritic dermatologic conditions besides atopic dermatitis or psoriasis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream, gel, ointment, solution (0.05%): Topical: Apply thin layer to affected area 2 to 4 times daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Cream (0.1%): Topical: Apply thin layer to affected area once or twice daily. Not recommended for use &gt;2 consecutive weeks or &gt;60 g/week total exposure. Therapy should be discontinued when control is achieved; if no improvement is seen within 2 weeks, reassess diagnosis.  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172320\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cream, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Vanos: 0.1% (30 g, 60 g, 120 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 30 g, 60 g, 120 g); 0.1% (30 g, 60 g, 120 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gel, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 30 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ointment, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (15 g, 30 g, 60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, External: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.05% (20 mL, 60 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172307\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052888\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical: For topical use only. Apply sparingly in a thin film. Rub in lightly. Avoid contact with eyes; generally not for routine use on the face, underarms, or groin area. Unless otherwise directed by health care professional, do not use with occlusive dressing; do not use on skin covered by diapers or plastic pants. Wash hands after application (unless hands are part of the treatment area). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45099489\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">Store at room temperature; avoid excessive heat.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1052887\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluocinonide 0.05%: Cream, gel, ointment, topical solution: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA approved in pediatric patients [age not specified] and adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fluocinonide 0.1% cream: Relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (FDA approved in ages &ge;12 years and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172368\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Fluocinonide may be confused with flunisolide, fluocinolone </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lidex may be confused with Lasix, Videx</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172367\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Intracranial hypertension, localized burning</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Acne vulgaris, allergic dermatitis, atrophic striae, contact dermatitis, folliculitis, hypertrichosis, hypopigmentation, maceration of the skin, miliaria, perioral dermatitis, pruritus, skin atrophy, telangiectasia, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Endocrine &amp; metabolic: Cushing's syndrome, glycosuria, growth suppression, HPA-axis suppression, hyperglycemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Infection: Secondary infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Local: Local irritation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172325\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to fluocinonide or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172311\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Adrenal suppression: May cause hypercortisolism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Contact dermatitis: Allergic contact dermatitis can occur, it is usually diagnosed by failure to heal rather than clinical exacerbation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Kaposi sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi sarcoma (case reports); if noted, discontinuation of therapy should be considered (Goedert, 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Local effects: Local adverse reactions may occur (eg, skin atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection miliaria); may be irreversible. Local adverse reactions are more likely to occur with occlusive and/or prolonged use. If irritation develops, discontinued use and institute appropriate therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Skin infections: Concomitant skin infections may be present or develop during therapy; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Application site: Lower-strength formulations (0.05%) may be used cautiously on face or opposing skin surfaces that may rub or touch (eg, skin folds of the groin, axilla, and breasts); higher-strength (0.1%) should not be used on the face, groin, or axillae.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: 0.1% cream: Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week. Therapy should be discontinued when control of the disease is achieved. If no improvement is seen within 2 weeks, reassess diagnosis. Do not use more than half of the 120 g tube per week. Should not be used in the treatment of rosacea or perioral dermatitis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25820095\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids may be absorbed percutaneously. The extent of absorption is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, prolonged duration of use, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children. Hypothalamic-pituitary-adrenal (HPA) suppression may occur, particularly in younger children or in patients receiving high doses for prolonged periods; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress. Infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to larger skin surface area to body mass ratio; use with caution in pediatric patients. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299350\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172315\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13311&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ceritinib: Corticosteroids may enhance the hyperglycemic effect of Ceritinib. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Corticosteroids may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172316\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13277393\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed with corticosteroids in animal reproduction studies. Topical corticosteroids are preferred over systemic for treating conditions, such as psoriasis or atopic dermatitis in pregnant women; high-potency corticosteroids are not recommended during the first trimester. Topical products are not recommended for extensive use, in large quantities, or for long periods of time in pregnant women (Bae 2011; Koutroulis 2011; Leachman 2006). Information specific to the use of fluocinonide during pregnancy is limited (Valkova 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45703477\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Growth in pediatric patients; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172310\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Topical corticosteroids have anti-inflammatory, antipruritic, and vasoconstrictive properties. May depress the formation, release, and activity of endogenous chemical mediators of inflammation (kinins, histamine, liposomal enzymes, prostaglandins) through the induction of phospholipase A<sub>2</sub> inhibitory proteins (lipocortins) and sequential inhibition of the release of arachidonic acid. Fluocinonide is fluorinated corticosteroid considered to be of high potency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172324\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Dependent on formulation, amount applied, and nature of skin at application site; may be increased with inflammation or occlusion </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily urine; bile </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172326\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Fluocinonide Emulsified Base External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (30 g): $96.33</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Fluocinonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (60 g): $182.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (120 g): $1,651.69</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Vanos External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (60 g): $1,968.97</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Fluocinonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (15 g): $59.56</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Ointment</b> (Fluocinonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (60 g): $283.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Fluocinonide External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (60 mL): $97.19</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F172327\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Acderma (JP);</li>\n      <li>Amfulan (TW);</li>\n      <li>Biscosal (JP);</li>\n      <li>Cusigel (AE);</li>\n      <li>Delipo (JP);</li>\n      <li>Dermadex (PH);</li>\n      <li>Etonalin F (JP);</li>\n      <li>Flu-21 (IT);</li>\n      <li>Flubiol (JP);</li>\n      <li>Flunide (TW, VN);</li>\n      <li>Fluotsynonid (UA);</li>\n      <li>Glycobase (JP);</li>\n      <li>Hakelon (JP);</li>\n      <li>KC-F (JP);</li>\n      <li>Lidex (BE, BM, GR, KR, LU, PH);</li>\n      <li>Medrexim (JP);</li>\n      <li>Metosyn (BB, BF, BJ, BS, BZ, CI, CZ, DK, ET, GB, GH, GM, GN, GY, JM, KE, LR, MA, ML, MR, MU, MW, NE, NG, NO, PR, SC, SD, SL, SN, SR, TN, TT, TZ, UG, ZA, ZM, ZW);</li>\n      <li>Murukos F (JP);</li>\n      <li>Novoter (AE, BH, ES, QA);</li>\n      <li>Rauracid (JP);</li>\n      <li>Rufull (JP);</li>\n      <li>Simaron (JP);</li>\n      <li>Solunim (JP);</li>\n      <li>Tohsino (JP);</li>\n      <li>Topsym (AE, AT, BH, CH, CY, DE, EC, EG, IL, IQ, IR, JO, JP, KW, LB, LY, OM, PE, PT, QA, SA, SY, TW, YE);</li>\n      <li>Topsym F (AT);</li>\n      <li>Topsym Polyol (PY);</li>\n      <li>Topsyn (CR, DO, GT, HN, IT, MX, NI, PA, SV);</li>\n      <li>Topsyne (FR, NL);</li>\n      <li>Trappen (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinonide-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bae YS, Van Voorhees AS, Hsu S, et al. Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation. <i>J Am Acad Dermatol</i>. 2012;67(3):459-477.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinonide-pediatric-drug-information/abstract-text/22018758 /pubmed\" target=\"_blank\" id=\"22018758 \">22018758 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluocinonide cream [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals Inc; April 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fluocinonide topical solution [prescribing information]. Hawthorne, NY: Taro Pharmaceuticals Inc; October 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goedert JJ, Vitale F, Lauria C, et al. Risk factors for classical Kaposi's sarcoma. <i>J Natl Cancer Inst</i>. 2002;94(22):1712-1718.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinonide-pediatric-drug-information/abstract-text/12441327 /pubmed\" target=\"_blank\" id=\"12441327 \">12441327 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koutroulis I, Papoutsis J, Kroumpouzos G. Atopic dermatitis in pregnancy: current status and challenges. <i>Obstet Gynecol Surv</i>. 2011;66(10):654-663.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinonide-pediatric-drug-information/abstract-text/22112526 /pubmed\" target=\"_blank\" id=\"22112526 \">22112526 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leachman SA, Reed BR. The use of dermatologic drugs in pregnancy and lactation. <i>Dermatol Clin</i>. 2006;24(2):167-197. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinonide-pediatric-drug-information/abstract-text/16677965 /pubmed\" target=\"_blank\" id=\"16677965 \">16677965 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    NICE. Management of atopic eczema in children from birth up to the age of 12 years. Clinical guideline. December 2007. Available at http://www.nice.org.uk/guidance/cg57/evidence/full-guideline-196612237</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinonide-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Valkova S. Food-induced acute generalized exanthematous pustulosis in a pregnant woman.<i> Skinmed</i>. 2006;5(4):199-201.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/fluocinonide-pediatric-drug-information/abstract-text/16855416 /pubmed\" target=\"_blank\" id=\"16855416 \">16855416 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vanos (fluocinonide) [prescribing information]. Scottsdale, AZ: Medicis, The Dermatology Company; March 2012.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13311 Version 163.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F172332\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F172333\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1052884\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1052879\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F172320\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F172307\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1052888\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F45099489\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1052887\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F172368\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F172367\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F172325\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F172311\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F25820095\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299350\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F172315\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F172316\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13277393\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F45703477\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F172310\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F172324\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F172326\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F172327\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13311|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=fluocinonide-drug-information\" class=\"drug drug_general\">Fluocinonide: Drug information</a></li><li><a href=\"topic.htm?path=fluocinonide-patient-drug-information\" class=\"drug drug_patient\">Fluocinonide: Patient drug information</a></li></ul></div></div>","javascript":null}